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in benign luminal cells or usual-type adenocarcinoma. In contrast, ETS2 was highly expressed in 95% (18/19) of p63-expressing prostate carcinomas.
Conclusions: ETS2 is a predominantly basally-expressed gene in the prostate, with low expression in usual-type adenocarcinoma and high expression in p63-expressing carcinomas. Given this pattern, the significance of ETS2 loss by deletion or mutation in usual-type adenocarcinomas is uncertain.
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| INTRODUCTION
Prostate carcinomas aberrantly expressing p63 protein are a rare and molecularly distinct subclass of prostate cancer. [1] [2] [3] [4] Though generally indolent, the study of these unusual tumors provides unique insights into prostate cancer biology. We have previously demonstrated that p63-expressing prostate cancers express the ΔNp63 isoform of p63, 3, 4 though it is unknown whether it is transcriptionally active in these cells.
These tumors have an immunophenotype intermediate between prostatic basal and luminal cells, in contrast to usual-type adenocarci-
nomas which generally have a luminal phenotype. 3 Although they express androgen receptor and markers of prostatic origin such as NKX3.1, p63-expressing tumors do not appear to rearrange ERG at a detectable frequency (an alteration seen in half of usual-type adenocarcinomas) and many lack GSTP1 hypermethylation (an alteration seen in the vast majority of usual-type adenocarcinomas). 3 To better molecularly characterize these tumors, we compared gene expression profiling of formalin fixed paraffin embedded (FFPE) p63-expressing tumors to usual-type adenocarcinomas. We find that p63-expressing carcinomas show transcriptomic profiles consistent with their indolent clinical behavior, despite their apparently higher
Gleason grade by gene expression signatures and morphology. In addition, these tumors highly express a number of p63 target genes, suggesting active p63-mediated transcription. 
| Statistical analysis
Statistical analyses were performed in R v3.2.2, and all tests were two-sided using a 5% significance level. Fisher's exact test was used to study the association between categorical variables. Area Under Curve (AUC) was used for model performance evaluation. Pearson's correlation was used to find correlated genes to TP63. Wilcoxon rank sum test was used to evaluate differences in mean expression between groups. Kruskal Wallis test was used to analyze differences between ETS2 expression by RNAseq between groups. Spearman's correlation was used to examine correlation of p63 and ETS2 expression in RNAseq.
| RESULTS
We compared gene expression data from 8 p63-expressing carcinomas and 358 usual-type adenocarcinomas previously profiled. Initial comparisons by previously published gene expression classifiers revealed that p63-expressing carcinomas had low scores using the Decipher gene expression prognostic classifier compared to usual-type adenocarcinoma ( Figure 1A ) and relatively low cell cycle gene expression using genes in the CCP classifier ( Figure 1B ). 13 However, using a previously published gene expression signature that distinguishes Gleason score ≤6 from Gleason score ≥8 tumors, Table S1 ). First, for each gene we examined its correlation with TP63 gene expression across the GRID radical prostatectomy cohort (n = 5239) using the Pearson There were 104 genes differentially expressed between the two groups and p63-expressing carcinomas cluster together (maroon bars). B, Each of the 104 genes from (A) were graphed according to their correlation with TP63 gene expression in a large prospective radical prostatectomy cohort (GRID cohort, n = 5239) and the AUC for that gene in distinguishing the original 8 p63-expressing carcinomas from the 358 usual type adenocarcinomas. Genes with a high AUC and/or high correlation are highlighted in red. C, RNA expression levels for p63 were higher in the p63-expressing carcinomas compared to 358 usual-type adenocarcinomas, as expected (P = 0.004; Wilcoxon test). D, RNA expression levels for miR205 were higher in the p63-expressing carcinomas compared to 358 usual-type adenocarcinomas (P = 0.01; Wilcoxon test). miR205 is known to be regulated by the p63 transcription factor. 15 Figure 2E ) and suggested the possible hypothesis that p63-expressing carcinomas are driven by alternative ETS family genes.
However, because we have previously shown that p63-expressing carcinomas have a partially basal phenotype, 3 we first sought to determine whether ETS2 might itself be a primarily basally-expressed gene in the prostate. To do this, we examined RNA-seq data from 25 usual-type adenocarcinomas and their paired benign samples.
Strikingly, median ETS2 gene expression was markedly higher in benign prostate tissue compared to usual-type adenocarcinoma, a pattern that held true for nearly all paired samples ( Figures 3A and 3C) .
Consistent with the microarray data above, TP63 expression was correlated with ETS2 expression in benign and tumor samples ( Figure 3B ). These data suggested that ETS2 might be predominantly expressed in prostate basal cells which are sampled abundantly in benign prostate and are largely absent from tumor samples taken from usual-type adenocarcinomas.
To confirm our hypothesis that ETS2 is a primarily basallyexpressed gene, we used chromogenic RNA in situ hybridization to localize ETS2 expression across a spectrum of prostate tissues. In In differential gene expression analysis comparing p63-expressing carcinomas to usual-type adenocarcinomas, we were surprised to find that in addition to genes known to be directly regulated by p63, such as MIR205, ETS2 is among the genes whose over-expression best distinguishes p63-expressing carcinomas from usual-type carcinomas.
This finding was particularly intriguing as we have previously shown that ERG gene fusions, occurring in nearly half of usual-type prostate adenocarcinomas, do not occur at a measurable frequency among p63-expressing carcinomas, nor can ERG protein expression be detected in these tumors. 3 Based on RNA-seq and in situ hybridization data from benign prostate tissues, we find that ETS2 is highly expressed among benign basal cells in the prostate, and thus its high expression in p63-expressing carcinomas is likely part of a program of basal differentiation in these tumors. Based on these data, it is reasonable to hypothesize that ETS2 may be a direct target of p63-transcription in prostatic epithelial cells, though the correlation coefficient between p63 and ETS2 expression was notably lower than that seen for known p63 target MIR205 in our study. Intriguingly, a p63-family member, p53, can interact with ETS2. 20 In fact, p53
proteins harboring oncogenic missense mutations have an even stronger interaction with ETS2 than wild-type forms, binding to the tetra-dimerization domain of p53 and regulating gene transcription via ETS-binding site motifs. 20, 21 This interaction likely contributes to gainof-function phenotypes for mutant p53 in some contexts. 20, 21 Thus it is also conceivable that an ETS2-p63 interaction might contribute to transcriptional changes in p63-expressing prostate carcinomas. Johns Hopkins cases and the larger prospective GRID cohort) are skewed toward relatively high-risk disease as they were selected for prognostic studies (in the case of the former) or sent for further clinical molecular testing (in the case of the latter). Therefore, they may not be entirely representative of usual-type adenocarcinoma in the way that a consecutive case series might be, though the sheer size of the prospective cohort likely mitigates this weakness to some extent.
Finally, the in situ hybridization studies were performed on tissue microarrays, which limits ability to discern whether ETS2 expression showed intratumoral heterogeneity in the tumors examined.
In conclusion, we find that the rare subset of p63-expressing prostate carcinomas have gene expression profiles largely consistent with their indolent clinical behavior. Compared to usual-type adenocarcinomas, these tumors over-express genes such as MIR205
that are known targets of p63-mediated transcription, suggesting that p63 is both expressed and transcriptionally active in this rare subset of prostatic neoplasms. Finally, we find that ETS2 is a gene overexpressed in p63-expressing carcinomas and benign basal cells compared to benign luminal cells or usual-type adenocarcinoma, consistent with the basal differentiation seen in this rare tumor type.
Given our finding that ETS2 is predominantly a basally-expressed gene in the prostate, its potential role as a tumor suppressor gene in luminally-differentiated prostate cancer cells is uncertain.
